Gut microbial differences in breast and prostate cancer cases from two randomised controlled trials compared to matched cancer-free controls
- 15 June 2021
- journal article
- research article
- Published by Brill in Beneficial Microbes
- Vol. 12 (3), 239-248
- https://doi.org/10.3920/bm2020.0098
Abstract
Implicated in several chronic diseases, the gastrointestinal microbiome is hypothesised to influence carcinogenesis. We compared faecal microbiota of newly diagnosed treatment-naïve overweight and obese cancer patients and matched controls. Cases were enrolled in presurgical weight-loss trials for breast (NCT02224807) and prostate (NCT01886677) cancers and had a body mass index (BMI) ≥25 kg/m2. Cancer-free controls were matched 1:1 by age (±5 years), race, gender, and BMI (±5 kg/m2). All participants provided faecal samples; isolated bacterial DNA were PCR amplified at the V4 region of the 16S rRNA gene and analysed using the QIIME pipeline. Tests compared cases versus controls, then separately by gender. Microbial alpha-diversity and beta-diversity were assessed, and relative abundance of Operational Taxonomic Units (OTU’s) were compared at the genus level, with false discovery rate (FDR) correction. 22 overweight and obese cancer patients were matched with 22 cancer-free controls, with an average BMI of 30.5±4.3 kg/m2, age 54.4±5.3 years, and 54.5% were black. Fourteen matches were made between breast cancer cases and healthy female controls, and 8 matches were made with prostate cancer cases and healthy male controls. Comparison of all cases and controls revealed no differences in alpha diversity, though prostate cancer patients had higher Chao1 (P=0.006) and Observed Species (P=0.036) than cancer-free males. Beta-diversity metrics were significantly different between cases and controls (PP=0.005). Kruskal Wallis tests indicated significant differences among 16 genera in all matches, 9 in female, and 51 in male. This study suggests the faecal microbiota of treatment-naive breast and prostate cancer patients differs from controls, though larger samples are needed to substantiate these findings. Trial registration: NIH Clinical Trials, NCT01886677, NCT02224807, registered 26 June 2013, 25 Aug 2014 (respectively) – retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT01886677; https://clinicaltrials.gov/ct2/show/NCT02224807Keywords
This publication has 56 references indexed in Scilit:
- Structure, function and diversity of the healthy human microbiomeNature, 2012
- Towards the Human Colorectal Cancer MicrobiomePLOS ONE, 2011
- Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Immunity, Inflammation, and CancerCell, 2010
- An infernal triangleNature, 2007
- Metabolic Endotoxemia Initiates Obesity and Insulin ResistanceDiabetes, 2007
- Hydrogen Sulfide Induces Direct Radical-Associated DNA DamageMolecular Cancer Research, 2007
- Macrophage/Cancer Cell Interactions Mediate Hormone Resistance by a Nuclear Receptor Derepression PathwayCell, 2006
- The pathobiology of mucositisNature Reviews Cancer, 2004
- Is Hodgkin's disease a human counterpart of bacterially induced crown-gall tumours?The Lancet, 1995